Highlights

  • Cyclopharm (ASX:CYC) reported first-half 2026 revenue of AUD 17.5 million, up 14% year on year.
  • US revenue-generating Technegas sites increased to 70 at 30 June 2026 and 83 by 12 August.
  • The company recorded an AUD 8.8 million half-year net loss and held AUD 12.2 million in cash at June-end.
  • Chinese medical organisations recommended Technegas as a preferred lung ventilation imaging agent in October.

Cyclopharm Limited (ASX:CYC), an Australian nuclear medicine company, is expanding the clinical use and commercial availability of its Technegas lung imaging product. Its first-half 2026 report showed revenue growth alongside a wider network of US hospital installations, while an October clinical consensus in China added to developments in medical practice guidance. At the time of writing on 19 October 2026, Cyclopharm shares were trading at AUD 0.42, up 5.00% during the day’s trading session.

Company Business

Cyclopharm develops and supplies Technegas, a radiopharmaceutical ventilation agent used in nuclear medicine scans to assess airflow through the lungs. Patients inhale a finely dispersed technetium-labelled carbon material, which allows imaging equipment to show lung ventilation. In the United States, approved use includes assessment of pulmonary embolism alongside perfusion imaging for adults and children aged six years and older.

The group earns revenue from Technegas equipment access, installations, training and recurring consumables. It also operates a third-party distribution business for nuclear medicine products. Its geographic operations cover the United States and established markets across Europe, Asia-Pacific and elsewhere. The US rollout is a focus because each operating installation can create ongoing demand for single-patient consumables.

Recent Development

In October 2026, Cyclopharm announced that seven Chinese medical bodies had jointly issued an expert consensus recommending Technegas as the preferred radiopharmaceutical for ventilation imaging in pulmonary embolism. The consensus also addressed imaging for screening, follow-up and evaluation of treatment response in pulmonary embolism and chronic thromboembolic pulmonary hypertension. Clinical recommendations do not themselves establish new sales or guarantee purchasing decisions.

The Chinese publication followed July 2026 guidance developed by nuclear medicine organisations across the United States, Europe, Australia and New Zealand, which described Technegas as generally preferred when available. The company also reported an 11-site deployment at University Hospitals in the US during July, illustrating its approach to extending installations across existing healthcare networks.

At 12 August 2026, Cyclopharm reported 83 revenue-generating US sites, compared with 70 at the end of June. Its disclosed commercial pipeline included 1,684 actively engaged US sites, although engagement spans several stages and should not be equated with completed installations or contracted revenue.

Financial Performance and Sector Context

For the six months ended 30 June 2026, Cyclopharm reported revenue of AUD 17.5 million, an increase of 14% from the corresponding period. US Technegas revenue rose 74% to AUD 2.1 million. Technegas revenue outside the US increased 13% to AUD 7.3 million, while third-party distribution revenue rose 4% to AUD 8.1 million.

The half-year net loss after tax widened to AUD 8.8 million from AUD 7.7 million. Cyclopharm attributed the change to expenditure on its US commercial operations, research and development costs of AUD 0.57 million, and the absence of an AUD 1.1 million joint venture profit contribution recorded a year earlier. Group gross margin increased from 53.5% to 56.3%.

Cash stood at AUD 12.2 million on 30 June 2026 following a net AUD 13.5 million institutional placement and share purchase plan. The group operates within a regulated diagnostic imaging market where reimbursement arrangements, hospital procurement procedures and clinical guidelines affect adoption and utilisation.

Risks to Consider

Commercial execution remains important: hospital purchasing decisions, equipment installation and clinician training can lengthen deployment schedules. Changes to reimbursement, regulatory requirements or clinical practice could alter demand. Operating losses and spending on US expansion and clinical studies create ongoing cash-management considerations, while the benefits of new guidelines depend on how individual healthcare providers respond.

What to Watch Next

Future reporting can clarify how many US Technegas systems become revenue-generating, the utilisation of installed equipment and recurring consumable sales. Other monitoring points include the conversion of contracted and prospective hospital networks, further developments in China, clinical work on applications beyond pulmonary embolism, and subsequent cash flow and operating expenditure disclosures.

Key Insights

Cyclopharm’s 2026 first-half results show increasing revenue and wider US commercial deployment, accompanied by a larger net loss. New clinical guidance in China and earlier international guidance provide additional context for Technegas adoption. Installation conversion, recurring revenue, operating costs and cash balances remain measurable indicators for subsequent company updates.